Login to Your Account


DUBLIN – Immunoqure AG is parlaying an extensive auto-antibody characterization effort involving a cohort of patients with an ultra-rare autoimmune disease into an antibody discovery engine that has uncovered large numbers of highly active antibodies with the potential to address a swath of immunological conditions.

LONDON – Mina Therapeutics Ltd. is laying claim to be first in the clinic with a novel RNA therapeutic that, in contrast to its more established siRNA gene silencing counterparts, activates dormant genes.

After years of taking a back seat to research efforts in indications such as cardiovascular disease, cancer and pulmonary disease, the gastrointestinal space is hot.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: